Towards effective solid form screening

Journal of Pharmaceutical Sciences

Volumn 99, Issue 9, 2010, Pages 3711-3718

  Allesø, Morten ^a   Tian, Fang ^a   Cornett, Claus ^a   Rantanen, Jukka ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Amorphous; High throughput; near infrared (NIR) spectroscopy; Hydrate; Nifedipine; Polymorph screening; Process induced transformations (PITs); Raman spectroscopy; Theophylline

Indexed keywords

NIFEDIPINE; THEOPHYLLINE;

ARTICLE; CRYSTALLIZATION; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SCREENING; DRUG STABILITY; KINETICS; SOLID STATE;

EID: 77956358912     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21957     Document Type: Article

References (34)

1. McCrone WC. 1965. Polymorphism. In: Fox D, Labes MM, Weissberger A, editors. Physics and chemistry of the organic solid state. New York: Interscience Publishers. pp. 725-767.
2. Vippagunta SR, Brittain HG, Grant DJ. 2001. Crystalline solids. Adv Drug Deliv Rev 48:3-26.
3. Jarring K, Larsson T, Stensland B, Ymén I. 2006. Thermodynamic stability and crystal structures for polymorphs and solvates of formoterol fumarate. J Pharm Sci 95:1144-1161. (Pubitemid 43723171)
4. Singhal D, Curatolo W. 2004. Drug polymorphism and dosage form design: A practical perspective. Adv Drug Deliv Rev 56:335-347.
5. Chemburkar SR, Bauer J, Deming K, Spiwek H, Patel K, Morris J, Henry R, Spanton S, Dziki W, Porter W, Quick J, Bauer P, Donaubauer J, Narayanan BA, Soldani M, Riley D, McFarland K. 2000. Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development. Org Process Res Dev 4:413-417.
6. ICH 2000. Q6A Guideline. Specifications: Test procedures and acceptance criteria for new drug substances and new drug products: Chemical substances. International Conference on Harmonization.
7. Morissette SL, Almarsson Ö, Peterson ML, Remenar JF, Read MJ, Lemmo AV, Ellis S, Cima MJ, Gardner CR. 2004. High-throughput crystallization: Polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv Drug Deliv Rev 56:275-300.
8. Almarsson Ö, Hickey MB, Peterson ML, Morissette SL, Soukasene S, McNulty C, Tawa M, MacPhee JM, Remenar JF. 2003. High-throughput surveys of crystal form diversity of highly polymorphic pharmaceutical compounds. Cryst Growth Des 3:927-933. (Pubitemid 37467742)
9. Morissette SL, Soukasene S, Levinson D, Cima MJ, Almarsson Ö. 2003. Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization. Proc Natl Acad Sci USA 100:2180-2184.
10. Peterson ML, Morissette SL, McNulty C, Goldsweig A, Shaw P, LeQuesne M, Monagle J, Encina N, Marchionna J, Johnson A, Gonzalez-Zugasti J, Lemmo AV, Ellis SJ, Cima MJ, Almarsson Ö. 2002. Iterative high-throughput polymorphism studies on acetaminophen and an experimentally derived structure for form III. J Am Chem Soc 124:10958-10959.
11. Morris KR, Griesser UJ, Eckhardt CJ, Stowell JG. 2001. Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. Adv Drug Deliv Rev 48:91-114.
12. Zhang GGZ, Law D, Schmitt EA, Qiu YH. 2004. Phase transformation considerations during process development and manufacture of solid oral dosage forms. Adv Drug Deliv Rev 56:371-390. (Pubitemid 38202329)
13. Bauer-Brandl A. 1996. Polymorphic transitions of cimetidine during manufacture of solid dosage forms. Int J Pharm 140:195-206.
14. Jørgensen A, Rantanen J, Karjalainen M, Khriachtchev L, Räsänen E, Yliruusi J. 2002. Hydrate formation during wet granulation studied by spectroscopic methods and multivariate analysis. Pharm Res 19:1285-1291.
15. Wikström H, Marsac PJ, Taylor LS. 2004. In-line monitoring of hydrate formation during wet granulation using Raman spectroscopy. J Pharm Sci 94: 209-219.
16. Wardrop J, Law D, Qiu Y, Engh K, Faitsch L, Ling C. 2006. Influence of solid phase and formulation processing on stability of Abbott-232 tablet formulations. J Pharm Sci 95:2380-2392. (Pubitemid 44726379)
17. Brittain HG. 2002. Effects of mechanical processing on phase composition. J Pharm Sci 91:1573-1580.
18. Ghan GA, Lalla JK. 1992. Effect of compressional forces on piroxicam polymorphs. J Pharm Pharmacol 44:678-681.
19. Okumura T, Ishida M, Takayama K, Otsuka M. 2006. Polymorphic transformation of indomethacin under high pressures. J Pharm Sci 95:689-700.
20. Pirttimäki J, Laine E, Ketolainen J, Paronen P. 1993. Effects of grinding and compression on crystal-structure of anhydrous caffeine. Int J Pharm 95:93-99.
21. Shakhtshneider TP, Boldyrev VV. 1993. Phase-transformations in sulfathiazole during mechanical activation. Drug Dev Ind Pharm 19:2055-2067.
22. Chow K, Tong HH, Lum S, Chow AH. 2007. Engineering of pharmaceutical materials: An industrial perspective. J Pharm Sci 97:2855-2877.
23. Grant DJ, Byrn SR. 2004. A timely re-examination of drug polymorphism in pharmaceutical development and regulation. Adv Drug Deliv Rev 56:237-239.
24. Chan KLA, Fleming OS, Kazarian SG, Vassou D, Chryssikos GD, Gionis V. 2004. Polymorphism and devitrification of nifedipine under controlled humidity: A combined FT-Raman, IR and Raman microscopic investigation. J Raman Spectrosc 35:353-359.
25. Storey R, Docherty R, Higginson P, Dallman C, Gilmore C, Barr G, Dong W. 2004. Automation of solid form screening procedures in the pharmaceutical industry - How to avoid the bottlenecks. Crystallogr Rev 10:45-56. (Pubitemid 40026209)
26. Hilfiker R, Berghausen J, Blatter F, Burkhard A, De Paul SM, Freiermuth B, Geoffroy A, Hofmeier U, Marcolli C, Siebenhaar B, Szelagiewicz M, Vit A, von Raumer M. 2003. Polymorphism - Integrated approach from high-throughput screening to crystallization optimization. J Therm Anal Calorim 73:429-440.
27. Phadnis NV, Suryanarayanan R. 1997. Polymorphism in anhydrous theophylline-Implications on the dissolution rate of theophylline tablets. J Pharm Sci 86:1256-1263.
28. Kogermann K, Aaltonen J, Strachan CJ, Pollänen K, Heinämäki J, Yliruusi J, Rantanen J. 2008. Establishing quantitative in-line analysis of multiple solid-state transformations during dehydration. J Pharm Sci 97:4983-4999.
29. Savolainen M, Heinz A, Strachan C, Gordon KC, Yliruusi J, Rades T, Sandler N. 2007. Screening for differences in the amorphous state of indomethacin using multivariate visualization. Eur J Pharm Sci 30:113-123.
30. Burger A, Koller KT. 1996. Polymorphism and pseudopolymorphism of nifedipine. Sci Pharm 64: 293-301.
31. Grooff D, De Villiers MM, Liebenberg W. 2007. Thermal methods for evaluating polymorphic transitions in nifedipine. Thermochim Acta 454: 33-42. (Pubitemid 46185502)
32. Hirayama F, Wang Z, Uekama K. 1994. Effect of 2-hydroxypropyl-beta- cyclodextrin on crystallization and polymorphic transition of nifedipine in solid-state. Pharm Res 11:1766-1770.
33. Keymolen B, Ford JL, Powell MW, Rajabi-Siahboomi AR. 2003. Investigation of the polymorphic transformations from glassy nifedipine. Thermochim Acta 397:103-117.
34. Govindarajan R, Suryanarayanan R. 2006. Processing-induced phase transformations and their implications on pharmaceutical product quality. In: Hilfiker R, editor. Polymorphism in the pharmaceutical industry. Weinheim: Wiley-VCH. pp. 333-364.